Study S001180

Effect on Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis in Patients With Type 2 Diabetes Mellitus on Treatment With Gastric Inhibitory Polypeptide / Glucagon Like Peptide-1 Analogue (Tirzpatide)

ClinicalTrials.gov record

Registration

Registration: NCT05751720
Study type: INTERVENTIONAL
Phase: PHASE1; PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 30
Start: 2023-10-01
Primary completion: 2024-10
Lead sponsor: Dr Adnan Agha
Conditions: Non-Alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis; Type 2 Diabetes; Liver Fat
Interventions: DRUG:GIP/GLP-1a
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

change in liver stiffness in terms of kPa [12 months]
Change in Liver fat quantification [12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.